BACKGROUND: While statin drugs are recommended for secondary prevention of coronary heart disease (CHD), there is no medical consensus on whether or not a statin should be added to lifestyle change efforts for primary prevention of CHD. Previous research suggests that exposure to direct-to-consumer advertising (DTCA) increases drug demand among those at comparatively low risk. Research has yet to examine whether individual-level DTCA exposure may influence statin use among men and women at high, moderate, or low risk for future cardiac events. OBJECTIVE: To determine the relationship between estimated exposure to DTCA for statin drugs and two clinical variables: diagnosis with high cholesterol and statin use. DESIGN: We used logistic regression to analyze repeated cross-sectional surveys of the United States population, merged with data on the frequency of DTCA appearances on national, cable, and local television, between 2001 and 2007. PARTICIPANTS: American adults (n=106,685) aged 18 and older. MAIN MEASURES: Levels of exposure to statin DTCA, based on ad appearances and TV viewing patterns; self-reports of whether or not a respondent has been diagnosed with high cholesterol, and whether or not a respondent took a statin in the past year. KEY RESULTS: Adjusting for potential confounders, we estimate that exposure to statin ads increased the odds of being diagnosed with high cholesterol by 16 to 20 %, and increased statin use by 16 to 22 %, among both men and women (p<0.05). These associations were driven almost exclusively by men and women at low risk for future cardiac events. There was also evidence of a negative association between DTCA exposure and statin use among high-risk women (p<0.05) CONCLUSIONS: This study provides new evidence that DTCA may promote over-diagnosis of high cholesterol and over-treatment for populations where risks of statin use may outweigh potential benefits.
BACKGROUND: While statin drugs are recommended for secondary prevention of coronary heart disease (CHD), there is no medical consensus on whether or not a statin should be added to lifestyle change efforts for primary prevention of CHD. Previous research suggests that exposure to direct-to-consumer advertising (DTCA) increases drug demand among those at comparatively low risk. Research has yet to examine whether individual-level DTCA exposure may influence statin use among men and women at high, moderate, or low risk for future cardiac events. OBJECTIVE: To determine the relationship between estimated exposure to DTCA for statin drugs and two clinical variables: diagnosis with high cholesterol and statin use. DESIGN: We used logistic regression to analyze repeated cross-sectional surveys of the United States population, merged with data on the frequency of DTCA appearances on national, cable, and local television, between 2001 and 2007. PARTICIPANTS: American adults (n=106,685) aged 18 and older. MAIN MEASURES: Levels of exposure to statin DTCA, based on ad appearances and TV viewing patterns; self-reports of whether or not a respondent has been diagnosed with high cholesterol, and whether or not a respondent took a statin in the past year. KEY RESULTS: Adjusting for potential confounders, we estimate that exposure to statin ads increased the odds of being diagnosed with high cholesterol by 16 to 20 %, and increased statin use by 16 to 22 %, among both men and women (p<0.05). These associations were driven almost exclusively by men and women at low risk for future cardiac events. There was also evidence of a negative association between DTCA exposure and statin use among high-risk women (p<0.05) CONCLUSIONS: This study provides new evidence that DTCA may promote over-diagnosis of high cholesterol and over-treatment for populations where risks of statin use may outweigh potential benefits.
Authors: Michele M Spence; Stephanie S Teleki; T Craig Cheetham; Stuart O Schweitzer; Mirta Millares Journal: Med Care Res Rev Date: 2005-10 Impact factor: 3.929
Authors: Richard L Kravitz; Ronald M Epstein; Mitchell D Feldman; Carol E Franz; Rahman Azari; Michael S Wilkes; Ladson Hinton; Peter Franks Journal: JAMA Date: 2005-04-27 Impact factor: 56.272
Authors: Andrew R Robinson; Kirsten B Hohmann; Julie I Rifkin; Daniel Topp; Christine M Gilroy; Jeffrey A Pickard; Robert J Anderson Journal: Arch Intern Med Date: 2004-02-23
Authors: Hsien-Yen Chang; Irene Murimi; Matthew Daubresse; Dima M Qato; Sherry L Emery; G Caleb Alexander Journal: Med Care Date: 2017-08 Impact factor: 2.983
Authors: Richard L Kravitz; Peter Franks; Mitchell D Feldman; Daniel J Tancredi; Christina A Slee; Ronald M Epstein; Paul R Duberstein; Robert A Bell; Maga Jackson-Triche; Debora A Paterniti; Camille Cipri; Ana-Maria Iosif; Sarah Olson; Steven Kelly-Reif; Andrew Hudnut; Simon Dvorak; Charles Turner; Anthony Jerant Journal: JAMA Date: 2013-11-06 Impact factor: 56.272
Authors: Helen W Sullivan; Amie C O'Donoghue; Molly Lynch; Mihaela Johnson; Christine Davis; Douglas J Rupert Journal: Med Decis Making Date: 2019-10-04 Impact factor: 2.583